Core Insights - Endeavour Silver Corp. experienced a transformative year in 2025, marked by significant production growth, record revenues, and strategic milestones that enhance its asset portfolio and position for sustained growth [2] Financial Performance - In 2025, the company produced 6,486,661 ounces of silver and 37,164 ounces of gold, with total silver equivalent production reaching 11.2 million ounces, a 48% increase from 2024 [6][22] - Revenue for 2025 totaled $467.5 million, a 115% increase compared to 2024, driven by higher metal prices and a 36% increase in silver ounces sold [6][22] - Mine operating cash flow before taxes was $156.3 million, significantly up from $72.3 million in 2024 [6][22] - The company reported a net loss of $119.1 million for the year, compared to a net loss of $31.5 million in 2024 [24] Production and Costs - Direct operating costs per tonne increased to $152.79, an 8% rise from 2024, primarily due to the addition of the Terronera mine [19][22] - Consolidated cash costs per silver ounce increased by 34% to $17.34, driven by higher operating costs and lower by-product sales from Bolañitos [20][22] - All-in sustaining costs per silver ounce rose by 32% to $31.52, influenced by higher capital expenditures and corporate costs [21][22] Strategic Developments - The company successfully commissioned the Terronera mine and completed the acquisition of Minera Kolpa, enhancing its asset portfolio [2][6] - A definitive agreement was made to sell the Bolañitos mine for $30 million in cash and shares, with contingent consideration based on production milestones [6][22] - The company closed a $350 million convertible notes offering to repay debt and fund further development, particularly at the Pitarrilla project [6][22] Operational Highlights - Terronera commenced commercial production on October 1, 2025, processing 154,180 tonnes in Q4 2025 [6][22] - The company processed a total of 1,464,590 tonnes in 2025, significantly higher than the 781,439 tonnes processed in 2024 [18][22] - The realized silver price for 2025 was $40.73 per ounce, a 49% increase from the previous year, while the realized gold price was $3,591 per ounce, up 50% [22]

Core Insights - ANI Pharmaceuticals experienced significant growth in 2025, particularly in its Rare Disease and Generics segments, leading to an increase in both revenue and net income [2][7][10]. Financial Performance - Total net revenues for Q4 2025 reached $247.1 million, a 29.6% increase year-over-year, while full-year revenues were $883.4 million, up 43.8% [7][9]. - Rare Disease revenues for Q4 2025 were $131.3 million, reflecting a 50.8% increase year-over-year, with Cortrophin Gel contributing $111.4 million, an 87.6% increase [10][8]. - Generics net revenues were $100.8 million in Q4 2025, a 28.2% increase from the previous year, and $384.1 million for the full year, up 27.6% [4][11]. Product Highlights - Cortrophin Gel's growth was driven by new patient starts and an expanded sales force, with plans to enhance the Rare Disease organization by approximately 90 personnel to target acute gouty arthritis [8][10]. - ILUVIEN generated $19.8 million in Q4 2025 and $74.9 million for the full year, with ongoing commercial initiatives to improve patient access [8][10]. Profitability Metrics - GAAP net income for Q4 2025 was $27.5 million, or $1.18 per diluted share, compared to a net loss of $10.7 million in the prior year [15]. - Adjusted non-GAAP EBITDA for Q4 2025 was $65.4 million, a 30.6% increase year-over-year, driven by higher revenues and gross profit [16]. Guidance for 2026 - The company anticipates total net revenues for 2026 to be between $1,055 million and $1,115 million, representing a growth of 19% to 26% compared to 2025 [19]. - Cortrophin Gel is expected to generate revenues between $540 million and $575 million in 2026, indicating a growth of 55% to 65% [19].

Core Insights - Stacey Caywood has officially taken over as CEO of Wolters Kluwer, succeeding Nancy McKinstry, with a focus on AI investment and partnerships to drive growth [1][3] Company Overview - Wolters Kluwer is a global leader in information solutions, software, and services for professionals in various sectors including healthcare, tax, legal, and corporate performance [4] - The company reported annual revenues of €6.1 billion for 2025 and operates in over 180 countries with approximately 21,100 employees [5] Leadership and Strategy - Stacey Caywood has a proven track record in transforming and growing businesses at Wolters Kluwer, particularly in her previous roles in Legal & Regulatory and Health divisions [2] - The new CEO aims to accelerate AI-powered innovation across the company's portfolio, leveraging trusted content and domain expertise to enhance decision-making for professionals [3] - The near-term agenda includes expanding AI capabilities, developing partnerships, and strengthening commercial capabilities to drive growth [3]

Core Viewpoint - Jura Energy Corporation is facing a legal claim from minority shareholder Mr. Shahzad Zaheer, which alleges regulatory breaches related to a share acquisition transaction [1][3]. Group 1: Legal Proceedings - Mr. Zaheer has filed a Statement of Claim in the Ontario Superior Court of Justice against Jura and its directors [1]. - The claim includes allegations that the acquisition of Jura shares by IDL Investments Limited breached statutory and regulatory requirements [3]. - Jura disputes these allegations, asserting that no prior governmental consent was necessary for the transaction [3]. - Mr. Zaheer previously challenged the validity of the transaction in the Islamabad High Court, but that proceeding has been dismissed [5]. Group 2: Company Response - Jura believes the claim is without merit and intends to vigorously defend against it while seeking costs [6]. - The company is currently engaged in enforcement efforts related to a multi-million US dollar arbitration loss by Petroleum Exploration (Private) Limited, owned by Mr. Zaheer [2][6]. - Jura has responded to a show cause notice from Pakistan's Directorate General Petroleum Concessions regarding the transaction and continues to cooperate with authorities [4]. Group 3: Company Background - Jura Energy Corporation is an international energy company involved in the exploration, development, and production of petroleum and natural gas properties in Pakistan [11]. - The company operates through its subsidiaries, Frontier Holdings Limited and Spud Energy Pty Limited, and is listed on the TSXV under the symbol JEC [11].

Group 1 - Banco Itaú Chile announced its Management Commentary for the fourth quarter ended December 31, 2025 [1] - A conference call to discuss the financial results will be hosted on March 2nd, 2026, at 11:00 A.M. Santiago time [1] - The conference call will feature the company's CEO, CFO, and Chief Economist [1] Group 2 - Participants must pre-register to join the webinar [2] - Registration will provide details to connect to the call [2] Group 3 - A Q&A session will be available for participants during the webinar [3] - Attendees will have the opportunity to present questions, with selected questions answered verbally [3] Group 4 - Investor Relations contact information is provided for further inquiries [4]

Core Viewpoint - Ipsen announced a positive opinion from the CHMP recommending conditional marketing authorization for Ojemda® (tovorafenib) to treat pediatric low-grade glioma (pLGG) in patients aged 6 months and older with specific BRAF alterations who have progressed after prior therapies [1][7]. Group 1: Treatment Landscape - Over 800 new cases of BRAF altered pLGG are identified annually in the EU, leading to significant disabilities and a complex treatment journey involving surgeries and multiple therapies [2][16]. - Current treatment options for relapsed/refractory pLGG have been limited for decades, highlighting the need for targeted therapies like tovorafenib [4]. Group 2: Clinical Data and Efficacy - The positive CHMP opinion is based on the Phase II FIREFLY-1 study, which involved 137 children and young adults with relapsed or refractory BRAF-altered pLGG [4][14]. - The study showed an overall response rate of 71% per RANO-HGG criteria and 53% per RAPNO-LGG criteria, with a clinical benefit rate of 77% and 58% respectively [6]. - Among responders, the median time to response was 5.4 months, and the median duration of response was 18.0 months [6]. Group 3: Safety and Administration - Tovorafenib demonstrated a manageable safety profile, with a low discontinuation rate of 9.5% due to treatment-related adverse events, which were primarily Grade 1 or 2 [6]. - The drug offers convenient once-weekly oral dosing, available in both liquid and tablet forms, minimizing disruption to patients' daily routines [6]. Group 4: Regulatory Status and Future Prospects - Following the positive opinion from the CHMP, the European Commission will review the recommendation, with a final decision on marketing authorization expected soon [7]. - Tovorafenib is already approved in the U.S. for similar indications and has received Breakthrough Therapy and Rare Pediatric Disease designations from the FDA [11][9].

Core Insights - The company reported a strong financial performance in 2025, with total revenue reaching EUR 53.2 million, a significant increase from EUR 18.2 million in 2024, and a fourth-quarter revenue of EUR 18.9 million compared to EUR 7.6 million in the same period last year [18][24]. Real Estate Development - In Tallinn, the construction of the white building in the Uus-Kindrali project was completed, with 39 residential units closed by year-end and 78% of the sellable area sold [1][2]. - A second residential building with 90 units is under construction, targeting completion in October-November 2026 [3]. - The company is pursuing additional projects in Kristiine City, aiming to add approximately 35,000 square meters of gross building area, with a building permit obtained for the Tondi 53 project [4][5]. Financial Performance - The gross profit for 2025 was EUR 18.8 million, up from EUR 5.4 million in 2024, with a gross profit margin of 35% [21][24]. - Operating profit for the year was EUR 14.7 million, compared to EUR 0.1 million in 2024, reflecting a significant improvement in operational efficiency [21][24]. - The net profit for 2025 was EUR 12.0 million, a turnaround from a loss of EUR 3.9 million in 2024, with earnings per share increasing to EUR 0.22 from a loss of EUR 0.06 [22][24]. Market Conditions - The company noted a softening in occupancy levels in hotel operations towards the end of the year, particularly in the leisure segment, although food and beverage revenue showed a modest year-on-year increase [12]. - In Italy, operations faced challenges due to subdued market activity, but the fundamentals of the bare ownership model remain strong, indicating potential for future growth [13][14]. Strategic Outlook - The company emphasized disciplined execution and long-term planning as key drivers of value creation, with a focus on delivering high-quality projects and advancing its strategic goals [15][16]. - The management expressed confidence in the company's ability to maintain sustainable growth, supported by a solid project pipeline and favorable market conditions [17].

Core Insights - Amneal Pharmaceuticals reported strong financial performance for the full year 2025, meeting or exceeding all guidance metrics, with expectations for continued growth in 2026 [1][2] Financial Performance - Q4 2025 net revenue was $814 million, an 11% increase from $731 million in Q4 2024 [3] - Full year 2025 net revenue reached $3.02 billion, an 8% increase from $2.79 billion in 2024 [4] - Q4 2025 GAAP net income was $35 million, compared to a net loss of $31 million in Q4 2024 [3] - Full year 2025 GAAP net income was $72 million, a significant recovery from a net loss of $117 million in 2024 [4] Adjusted Financial Metrics - Q4 2025 adjusted net income was $68 million, with adjusted EBITDA of $175 million, reflecting a 13% increase from Q4 2024 [3] - Full year 2025 adjusted EBITDA was $688 million, a 10% increase compared to the previous year [4] - Adjusted diluted EPS for Q4 2025 was $0.21, up from $0.12 in Q4 2024 [3] - Full year 2025 adjusted diluted EPS was $0.83, compared to $0.58 in 2024 [4] Business Segments Performance - Specialty segment revenue grew by 38% in Q4 2025, driven by products like CREXONT® and UNITHROID® [3] - Affordable Medicines segment revenue decreased by 1% due to timing issues with key products [3] - AvKARE segment revenue increased by 24%, attributed to growth in government label sales [3] 2026 Financial Guidance - The company provided guidance for 2026, projecting net revenue between $3.05 billion and $3.15 billion, adjusted EBITDA between $720 million and $760 million, and adjusted diluted EPS between $0.93 and $1.03 [1][6][7] - Affordable Medicines net revenue is expected to grow by 7% to 8%, while Specialty revenue is projected to remain flat year-over-year [7]

LOUISVILLE, Ky., Feb. 27, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced financial results for the fourth quarter and full year ended December 31, 2025 and initiated full year 2026 Revenue and Adjusted EBITDA1 guidance. Fourth Quarter 2025 Financial Highlights(note: all figures represent continuing operations and exclude the Community Living b ...

Core Insights - Bekaert has achieved ISCC PLUS certification for its steel tire reinforcement products, highlighting its commitment to sustainability and innovation in the tire industry [1][5][6] Group 1: Certification and Standards - The Bekaert Recycled Content Standard has been a significant industry benchmark, facilitating traceability and sustainable practices in steel tire reinforcement, which contributed to the expansion of ISCC's certification framework [2][5] - A structured certification pathway for high recycled content in tire cord and bead wire has been established through collaboration among Bekaert, ISCC, and TÜV NORD [3][4] - The certification process involved auditing Bekaert's Burgos plant by TÜV NORD, ensuring the ISCC PLUS framework's reliable application to steel products [4][6] Group 2: Industry Impact - The certification positions Bekaert as a leader in certified tire reinforcement, promoting industry-wide adoption and creating value for tire manufacturers [5][6] - Tire manufacturers can leverage ISCC PLUS-certified materials for credible sustainability claims, simplifying compliance with regulatory and market requirements [5][6] - The successful certification process demonstrates the applicability of the ISCC framework to new material categories, enhancing traceability and sustainability assurance in industrial materials [6]